[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"inTumo Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":77},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100622246","intupro-in-the-treatment-of-benign-prostatic-hyperplasia-related-symptoms-100622246",false,"NCT07381127","INTUPRO in the Treatment of Benign Prostatic Hyperplasia-Related Symptoms","A Study to Evaluate the Safety and Efficacy of Ionic Fluid in Treating Symptoms in Patients With Benign Prostatic Hyperplasia. A Prospective, Single-arm, Single-center Clinical Study.","Inclusion Criteria:\n\n* • Male patient aged 45 years or older\n\n  * Prostate volume greater than 30 grams\n  * An International Prostate Symptom Score (IPSS) of 12 or higher\n  * Presence of obstructive urinary symptoms, such as difficulty starting urination, leakage of urine after voiding, or a feeling of incomplete bladder emptying.\n\nThis criterion may include patients who have previously been diagnosed with prostate cancer and completed treatment, but are experiencing urinary problems.\n\n* Life expectancy of at least 3 months\n* Ability to understand the study information and provide written informed consent\n* Willingness and ability to comply with all study requirements, including procedures, clinical assessments, and follow-up visits\n\nExclusion Criteria:\n\n* Urethral stricture\n\n  * Bladder stones\n  * Prostate volume 120 grams or greater\n  * Presence of a prostate median lobe\n  * History of bladder cancer or kidney cancer, and\u002For prior surgery related to these conditions\n  * Previous radiation therapy to the pelvic region\n  * Prior invasive surgical treatment for BPH symptoms\n  * The Principal Investigator believes the patient would not tolerate the procedure\n  * Presence of a cognitive impairment that, in the opinion of the Principal Investigator, would interfere with the patient's ability to provide reliable data or to safely complete the study\n  * Bleeding disorders\n  * Known allergy or intolerance to MRI contrast agents required for imaging used to evaluate treatment effectiveness after ionic fluid application\n  * Other significant concurrent medical conditions that, in the investigator's judgment, could prevent clinical benefit from the procedure or could place the patient or study objectives at risk (including, but not limited to, active infection, kidney dysfunction, or significant comorbidities)\n  * Significant medical or psychiatric illness\n  * Participation in another clinical study involving a device, drug, or procedure that has not been completed or that could affect the outcomes of this study\n  * Inability or unwillingness to undergo MRI examinations during the study period for any reason","MALE","45 Years",{"count":19,"type":20},31,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to determine whether INTUPRO can improve the quality of life in patients with Benign Prostate Hyperplasia (BPH).\n\nThe main questions it aims to answer are:\n\nCan INTUPRO treatment lead to the removal of the Foley catheter? Can INTUPRO treatment improve urinary flow? Can INTUPRO treatment lower or minimize waking during sleep to urinate? Can INTUPRO reduce urinary hesitancy, urgency and frequency?\n\nParticipants will:\n\nReceive INTUPRO treatment on Day 1. Visit at Day 30 and Day 90 for checkups, tests and Prostate MRI.",[26,27,28],"BPH (Benign Prostatic Hyperplasia)","BPH","BPH With Other Lower Urinary Tract Symptoms",[30,31,32,33,34],"procedure","needle","benign prostate hyperplasia","moderate sedation","outpatient","RECRUITING","2026-01-23",{"date":38,"type":39},"2026-02-02","ACTUAL",{"date":41,"type":39},"2025-03-04",{"date":43,"type":20},"2027-12",{"name":45,"class":46},"inTumo Therapeutics, Inc.","INDUSTRY",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":76,"locationsCount":47},"100569086","needle-based-percutaneous-ablation-of-liver-tumors-100569086","NCT06689670","Needle-based Percutaneous Ablation of Liver Tumors.","To Evaluate the Safety and Performance of INT001 in the Percutaneous Ablation of Liver Tumors: A Prospective, Single-arm, Single-center Clinical Study","Inclusion Criteria:\n\n1. Diagnosis of primary or secondary liver cancer.\n2. ECOG Performance Status score of 0 - 2\n3. Age ≥18 years, \\\u003C100 years\n4. Life expectancy of ≥3 months\n5. Patient is unsuitable for surgical resection or transplantation\n6. Ability of the patient to understand and sign the Informed Consent Form describing the study's nature\n7. Volunteer's willingness and ability to comply with protocol requirements, including all procedures, clinical evaluations, and follow-up visits\n\nExclusion Criteria:\n\n1. Decompensated liver function, specifically Child-Pugh C, moderate to severe ascites, coagulopathy, or severe cirrhosis.\n2. Signs of liver dysfunction: AST or ALT \\>5 times the upper limit of normal (ULN), Serum bilirubin level \\>2.0 mg\u002FdL\n3. Individuals with bleeding disorders.\n4. History of allergy or intolerance to contrast agents to be used during imaging for assessing treatment efficacy after INT001 application.\n5. Patients with life-threatening serious extrahepatic disease.\n6. Patients with concurrent conditions that, in the investigator's opinion, would prevent clinical benefit from the study procedure or could compromise patient safety or study objectives (including but not limited to ongoing infection, renal dysfunction, or morbidity).\n7. Significant medical or psychiatric illness.\n8. Pregnant or breastfeeding women or women planning to conceive within the next 6 months.\n9. Patients participating in another study investigating a device, drug, or procedure that may impact the study treatment outcome.\n10. Lesions that do not show contrast uptake on contrast-enhanced CT or MR angiography.\n11. Lesions that are not hypervascular on angiography.\n12. Patients who do not have CT or MR imaging available at the screening visit or are unwilling or unable to undergo MRI for various reasons during the study.","ALL","18 Years","100 Years",{"count":19,"type":20},[23],"The goal of this clinical trial is to learn if INT001 can ablate liver tumors in adults in an outpatient setting. It will also help us learn about the safety of INT001. The main questions it aims to answer are:\n\n1. Using a needle under image guidance, the liver tumor is accessed and INT001 is injected. Upon injection into tumor, does INT001 ablate\u002Fkill the tumor entirely?\n2. What medical problems do participants experience when receiving INT001?\n\nParticipants will:\n\nReceive INT001 on day 1. Visit the clinic day 7, 30 and 90. Receive lab tests during each visit and MRI on day 30 and 90.",[62,63,64],"Liver Tumors","HCC - Hepatocellular Carcinoma","Metastatic Liver Tumor",[66,67,68,31,69],"liver","tumor","ablation","out-patient","2026-01-15",{"date":72,"type":39},"2026-01-20",{"date":74,"type":39},"2024-10-28",{"date":43,"type":20},{"name":45,"class":46},""]